Natera Inc. ( (NTRA) ) has released its Q2 earnings. Here is a breakdown of the information Natera Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Natera, Inc. is a global leader in cell-free DNA and genetic testing, focusing on oncology, women’s health, and organ health, with operations in ISO 13485-certified and CAP-accredited laboratories in Austin, Texas, and San Carlos, California.
In its latest earnings report, Natera announced significant financial growth for the second quarter of 2025, with a notable increase in revenue and test processing volumes. The company has also raised its annual revenue outlook, reflecting strong performance across its product lines.
Key financial highlights include a 32.2% increase in total revenues to $546.6 million, driven by a similar rise in product revenues. Natera processed approximately 853,100 tests, marking a 12.2% increase from the previous year, with oncology tests seeing a substantial 50.6% rise. The company achieved a gross margin of 63.4%, up from 58.8% in the prior year, and reported a positive cash flow of $24.3 million.
Despite these gains, Natera reported a net loss of $100.9 million, influenced by legal accruals and stock-based compensation expenses. The company holds a strong cash position with $1,016.0 million in cash and equivalents, and a total outstanding debt of $80.3 million.
Looking ahead, Natera is optimistic about its growth prospects, anticipating total revenues between $2.02 billion and $2.10 billion for 2025, while maintaining its outlook for operating expenses. The company continues to focus on expanding its innovative product offerings to enhance patient care.